CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 69 enrolled
Drug / intervention
SAGE-718 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05358821
NCT05358821Phase 2Completed
CompareCT.gov

A 28-Day Randomized, Placebo-Controlled, Double-Blind, Parallel Groups and Normative Comparison Study to Evaluate the Effect of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease

Supernus Pharmaceuticals, Inc.·interventional·Posted May 3, 2022·Updated Sep 15, 2025

In Brief

A Phase 2 clinical trial evaluating SAGE-718 and Placebo for Huntington Disease. Completed, enrolled 69 participants across 14 sites in 2 countries.

Detailed Summary

The primary purpose of this study is to assess the magnitude of the baseline difference between participants with early Huntington's Disease (HD) and healthy participants (HP) with respect to measures of cognitive performance.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHuntington Disease
CountriesCanada, United States
Collaborators--

Timeline

Phase 2CompletedFinished
2023202420252026
First PostedMay 3, 2022
Enrollment StartMay 26, 2022
Primary CompletionFeb 29, 2024
Study CompletionApr 10, 2024
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 4.2 years ago

Interventions

SAGE-718drug

SAGE-718 oral softgel lipid capsules

Placebodrug

SAGE-718-matching oral capsules